

RESEARCH AND DEVELOPMENT · SWEDEN

PRESS RELEASE

FERROVITOS receives PIC number and sets its sights on the EIC Accelerator

– for continued research and innovation development

Eksjö, Sweden · 26 October 2026

PIC

registered in the EU Funding & Tenders Portal

€2.5 m

maximum grant, up to 70% of costs

€1–10 m

possible equity investment

79 of 80

completed the FE-MININ study

FERROVITOS AB, a wholly owned Swedish subsidiary of Bio Vitos Ltd, has received a PIC number in the EU Funding & Tenders Portal. The company thereby takes an important administrative step towards participating in European funding programmes and intends to prepare an application to the EIC Accelerator.

FERROVITOS has been established as the Swedish research and development platform within the Bio Vitos group. The ambition is to build on the group's clinical work in iron deficiency and strengthen the link between research, product development and future commercialisation.

The PIC number, *Participant Identification Code*, identifies FERROVITOS in the EU's application system. The registration provides the administrative identity required for applications; the eligibility of the company and the project is then assessed under the terms of the relevant call.

“

Our goal is to build a long-term research operation in Sweden that can turn scientific progress into tangible patient benefit. With the PIC number in place, we are moving ahead with designing the project documentation, budget and funding strategy. The EIC Accelerator is a priority track for innovations in our business that meet the programme's requirements.

Cato Crogh · Chairman of the Board of the parent company Bio Vitos Ltd

FROM REGISTRATION TO APPLICATION

01

DONE

PIC number

Registered in the EU Funding & Tenders Portal, October 2026.

02

ONGOING

Project documentation

Design the project plan, budget and funding strategy.

03

NEXT

Requirements review

Assess innovation, maturity, SME status and rights.

04

GOAL

EIC application


Prepare an application to the EIC Accelerator.

Funding from development to market

The EIC Accelerator is part of Horizon Europe and supports breakthrough innovations with strong commercial potential. The programme focuses on later stages of development and scale-up, and normally offers funding in three forms – separately or in combination:

Grant up to €2.5 m Just under €2.5 million, covering a maximum of 70 per cent of eligible costs.	Equity investment €1–10 m Investment through the EIC Fund, for example in shares or convertible instruments.	Combination Grant + equity So-called blended finance, combining grant and investment.
--	--	---

The grant component covers a maximum of 70 per cent of eligible costs. The remaining funding must be arranged by the company. For grant-funded activities the focus is on technology readiness levels TRL 6–8, which requires that the innovation has already been validated in a relevant environment.



What will be assessed before applying

FERROVITOS will review the project against the programme's requirements before an application is submitted:

✓ Level of innovation How groundbreaking the innovation is compared with existing solutions.	✓ Technical maturity That the innovation has been validated in a relevant environment.	✓ Commercial potential Market size and the route to commercialisation.
✓ Capital requirements Budget, co-financing and choice of funding form.	✓ SME status The company's status given the group's ownership structure.	✓ Rights and delivery Rights to the technology and results, and capacity to deliver.

Key facts

COMPANY	FERROVITOS AB, reg. no. 559528-4836
OWNER	Bio Vitos Ltd, 100 per cent
REGISTERED OFFICE	Eksjö, Sweden
PIC NUMBER	Received in the EU Funding & Tenders Portal, October 2026
PRIORITY TRACK	EIC Accelerator under Horizon Europe
RESEARCH PROGRAMMES	FE-MININ · MAXFERMAN · FE-MINI
ACADEMIC PARTNER	Linköping University, Prof. Fredrik Nyström

A Swedish base for continued iron research

The starting point is the Bio Vitos group's research programme, in which the participant phase of the FE-MININ study in women was carried out through Linköping University under the leadership of Professor Fredrik Nyström.

79/80

Of 80 participants, 79 completed the study. The high completion rate provides a solid basis for the continued analysis of iron status and iron supplementation in women – and for future studies within the group.

The continued research plan includes MAXFERMAN for men and the planned study direction FE-MINI for children with iron deficiency. FERROVITOS will develop funding documentation for relevant projects in line with each programme's terms.

FE-MININ

Women's iron health

**PARTICIPANT PHASE
COMPLETED**

Clinical study of iron treatment in women, carried out through Linköping University under Professor Fredrik Nyström. 79 of 80 participants completed. The results and continued analysis will guide future research efforts.

MAXFERMAN

Men's iron health

PLANNED

Planned clinical study of 80 men aged 25–55, with planned start on 15 January 2027. The study will broaden the knowledge base by investigating iron supplementation in men.

FE-MINI

Children's iron health

PLANNED DIRECTION

Planned study direction for children with iron deficiency. The intention is to develop a scientific design with particular regard to children's needs, safety and the ethical requirements for research involving minors.

The PIC number is a registration milestone. It does not mean that FERROVITOS has been approved for the EIC Accelerator or awarded funding.

About FERROVITOS AB

FERROVITOS AB is a wholly owned Swedish subsidiary of Bio Vitos Ltd. The company focuses on research and development in iron deficiency, clinical collaborations and building the scientific basis for future products and applications.

MORE INFORMATION
www.ferrovitos.com

Contact

Cato Crogh

Chairman of the Board, Bio Vitos Ltd
cato@payzinos.com

COMPANY DETAILS

FERROVITOS AB · Reg. no. 559528-4836
Norra Storgatan 29 b, 575 32 Eksjö
Parent company: Bio Vitos Limited, England and Wales.

FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements regarding, among other things, applications to EU programmes, eligibility, funding and upcoming studies. Actual outcomes may differ materially. No funding is guaranteed; decisions follow each programme's evaluation.

FERROVITOS · The research. The evidence. The collaboration.